JOP20210347A1 - طرق لعلاج فيروس نقص المناعة البشرية - Google Patents
طرق لعلاج فيروس نقص المناعة البشريةInfo
- Publication number
- JOP20210347A1 JOP20210347A1 JOP/2021/0347A JOP20210347A JOP20210347A1 JO P20210347 A1 JOP20210347 A1 JO P20210347A1 JO P20210347 A JOP20210347 A JO P20210347A JO P20210347 A1 JOP20210347 A1 JO P20210347A1
- Authority
- JO
- Jordan
- Prior art keywords
- rilpivirine
- methods
- pediatric patients
- treating hiv
- pediatric
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962870413P | 2019-07-03 | 2019-07-03 | |
| US16/919,677 US20210000823A1 (en) | 2019-07-03 | 2020-07-02 | Methods of treating hiv |
| PCT/EP2020/068913 WO2021001568A1 (en) | 2019-07-03 | 2020-07-03 | Methods of treating hiv in pediatric patients with rilpivirine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20210347A1 true JOP20210347A1 (ar) | 2023-01-30 |
Family
ID=71579550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2021/0347A JOP20210347A1 (ar) | 2019-07-03 | 2021-12-30 | طرق لعلاج فيروس نقص المناعة البشرية |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20210000823A1 (enExample) |
| EP (2) | EP3993799A1 (enExample) |
| JP (2) | JP2022538338A (enExample) |
| KR (2) | KR20220028049A (enExample) |
| CN (2) | CN114126655A (enExample) |
| AU (2) | AU2020300818A1 (enExample) |
| BR (2) | BR112021026916A2 (enExample) |
| CA (1) | CA3144307A1 (enExample) |
| IL (1) | IL289457A (enExample) |
| JO (1) | JOP20210347A1 (enExample) |
| MA (2) | MA56449A (enExample) |
| MX (2) | MX2022000060A (enExample) |
| PH (1) | PH12021553288A1 (enExample) |
| WO (2) | WO2021001508A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022538338A (ja) * | 2019-07-03 | 2022-09-01 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | リルピビリンを用いて小児患者におけるｈｉｖを治療する方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3429B1 (ar) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| AR065720A1 (es) * | 2007-03-14 | 2009-06-24 | Tibotec Pharm Ltd | Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso. |
| JP2014500261A (ja) * | 2010-11-19 | 2014-01-09 | ギリアード サイエンシーズ， インコーポレイテッド | リルピビリンＨＣｌおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物 |
| CA2921336A1 (en) * | 2015-06-30 | 2016-12-30 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| PT4070788T (pt) * | 2015-06-30 | 2023-06-06 | Gilead Sciences Inc | Formulações farmacêuticas |
| US11065198B2 (en) * | 2016-10-24 | 2021-07-20 | Janssen Sciences Ireland Unlimited Company | Dispersible compositions |
| CN110958883A (zh) * | 2017-06-30 | 2020-04-03 | Viiv保健公司 | 组合及其用途和疗法 |
| JP2022538338A (ja) * | 2019-07-03 | 2022-09-01 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | リルピビリンを用いて小児患者におけるｈｉｖを治療する方法 |
-
2020
- 2020-07-02 JP JP2021577856A patent/JP2022538338A/ja not_active Withdrawn
- 2020-07-02 AU AU2020300818A patent/AU2020300818A1/en not_active Abandoned
- 2020-07-02 BR BR112021026916A patent/BR112021026916A2/pt unknown
- 2020-07-02 US US16/919,677 patent/US20210000823A1/en not_active Abandoned
- 2020-07-02 KR KR1020227003258A patent/KR20220028049A/ko not_active Withdrawn
- 2020-07-02 WO PCT/EP2020/068734 patent/WO2021001508A1/en not_active Ceased
- 2020-07-02 EP EP20739584.9A patent/EP3993799A1/en active Pending
- 2020-07-02 MX MX2022000060A patent/MX2022000060A/es unknown
- 2020-07-02 CN CN202080048751.4A patent/CN114126655A/zh active Pending
- 2020-07-02 MA MA056449A patent/MA56449A/fr unknown
- 2020-07-03 CN CN202080048752.9A patent/CN114080223A/zh active Pending
- 2020-07-03 JP JP2021577871A patent/JP2022538449A/ja not_active Withdrawn
- 2020-07-03 AU AU2020300033A patent/AU2020300033A1/en not_active Abandoned
- 2020-07-03 CA CA3144307A patent/CA3144307A1/en active Pending
- 2020-07-03 WO PCT/EP2020/068913 patent/WO2021001568A1/en not_active Ceased
- 2020-07-03 BR BR112021026739A patent/BR112021026739A2/pt unknown
- 2020-07-03 MA MA056453A patent/MA56453A/fr unknown
- 2020-07-03 KR KR1020227003246A patent/KR20220028048A/ko not_active Withdrawn
- 2020-07-03 US US17/621,759 patent/US20220313693A1/en active Pending
- 2020-07-03 PH PH1/2021/553288A patent/PH12021553288A1/en unknown
- 2020-07-03 MX MX2021015627A patent/MX2021015627A/es unknown
- 2020-07-03 EP EP20742659.4A patent/EP3993800A1/en active Pending
-
2021
- 2021-12-28 IL IL289457A patent/IL289457A/en unknown
- 2021-12-30 JO JOP/2021/0347A patent/JOP20210347A1/ar unknown
-
2024
- 2024-01-10 US US18/408,900 patent/US20240139186A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210000823A1 (en) | 2021-01-07 |
| KR20220028048A (ko) | 2022-03-08 |
| CN114126655A (zh) | 2022-03-01 |
| MA56449A (fr) | 2022-05-11 |
| CN114080223A (zh) | 2022-02-22 |
| AU2020300818A1 (en) | 2022-03-03 |
| AU2020300033A1 (en) | 2022-02-24 |
| EP3993799A1 (en) | 2022-05-11 |
| BR112021026739A2 (pt) | 2022-04-26 |
| MA56453A (fr) | 2022-05-11 |
| MX2021015627A (es) | 2022-04-25 |
| PH12021553288A1 (en) | 2022-08-01 |
| CA3144307A1 (en) | 2021-01-07 |
| WO2021001568A1 (en) | 2021-01-07 |
| JP2022538338A (ja) | 2022-09-01 |
| EP3993800A1 (en) | 2022-05-11 |
| MX2022000060A (es) | 2022-04-18 |
| US20240139186A1 (en) | 2024-05-02 |
| BR112021026916A2 (pt) | 2022-05-10 |
| KR20220028049A (ko) | 2022-03-08 |
| IL289457A (en) | 2022-02-01 |
| WO2021001508A1 (en) | 2021-01-07 |
| JP2022538449A (ja) | 2022-09-02 |
| CA3144534A1 (en) | 2021-01-07 |
| US20220313693A1 (en) | 2022-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125089T1 (el) | Μεθοδοι για τη θεραπεια μολυνσεων απο coronaviridae | |
| JOP20210105B1 (ar) | مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp | |
| EA201391108A1 (ru) | Лечение липодистрофии | |
| BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
| EA201690687A1 (ru) | Ингибиторы репликации вируса иммунодефицита | |
| NZ713621A (en) | Compounds and methods of treating infections | |
| CO2021012579A2 (es) | Compuestos útiles en la terapia del vih | |
| EA202191133A1 (ru) | Сигнатуры интерферона типа i и способы их применения | |
| MX390722B (es) | Tratamiento de resistencia a diureticos. | |
| JOP20190056B1 (ar) | مركبات للاستخدام في علاج القصور الكلوي الحاد | |
| MX2019015212A (es) | Compuestos para el tratamiento del sarcoma. | |
| NZ758449A (en) | Heteroaromatic compounds useful in therapy | |
| EP3590338A3 (en) | Medical treatments based on anamorelin | |
| EA202190281A1 (ru) | Производные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диаза-спиро[4,5]декана | |
| MY199237A (en) | Methods of treating ocular conditions | |
| WO2016029136A8 (en) | 3-amidobenzamides and uses thereof for increasing cellular levels of a3g | |
| EA201792123A1 (ru) | Лечение боли | |
| WO2019040105A3 (en) | COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES | |
| EA201792056A1 (ru) | Лечение пациентов с сахарным диабетом 2 типа | |
| EA202090558A1 (ru) | Схемы лечения | |
| JOP20210347A1 (ar) | طرق لعلاج فيروس نقص المناعة البشرية | |
| EA202090266A1 (ru) | Ингибиторы mpo для применения в медицине | |
| EA201390925A1 (ru) | Производные санглиферина и способы их получения | |
| CO2025004675A2 (es) | Método para tratar vih con cabotegravir y rilpivirina en pacientes pediátricos | |
| EA201891922A1 (ru) | Лекарственное средство для лечения инфекций на фоне диабетической стопы |